Fertility outcomes post immune checkpoint inhibitor exposure.

Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies and healthy progeny. They demonstrate contemporaneous monitoring of temporal female hormonal fluctuations before, on, and post ICB exposure and prior to successful embryo implantation.
Competing Interests: Declaration of interests E.H. has received funding from the Conquer Cancer ASCO Foundation. She has served as a consultant to Pfizer Ireland on one occasion in 2021 and to Takeda on one occasion in 2024. She reports educational grants from Merck and Amgen to attend GI ASCO 2020. M.P. has received personal fees for consulting from BMS, Merck, Novartis, Eisai, Pfizer, Chugai, Erasca, and Nektar. He reports institutional support from the following companies: RGenix, Infinity, BMS, Merck, Novartis, BioAtla, and Genentech. A.C. has served on advisory boards for the following companies: Abbvie, Amgen, Agenus, Daiichi Saynko, Janssen, GSK, Merck, Pfizer/Seagen Regeneron, and Roche. She has research funding from GSK and Pfizer/Seagen. She holds a pending patent for Neoadjuvant PD1 blockade in locally advanced mismatch repair deficient solid tumors.
(Copyright © 2024 Elsevier Inc. All rights reserved.)